JP2024516998A - Shp2阻害剤とegfrチロシンキナーゼ阻害剤とを含む併用療法 - Google Patents
Shp2阻害剤とegfrチロシンキナーゼ阻害剤とを含む併用療法 Download PDFInfo
- Publication number
- JP2024516998A JP2024516998A JP2023567923A JP2023567923A JP2024516998A JP 2024516998 A JP2024516998 A JP 2024516998A JP 2023567923 A JP2023567923 A JP 2023567923A JP 2023567923 A JP2023567923 A JP 2023567923A JP 2024516998 A JP2024516998 A JP 2024516998A
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- egfr
- cancer
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184697P | 2021-05-05 | 2021-05-05 | |
| US63/184,697 | 2021-05-05 | ||
| US202263320991P | 2022-03-17 | 2022-03-17 | |
| US63/320,991 | 2022-03-17 | ||
| PCT/US2022/027693 WO2022235815A1 (en) | 2021-05-05 | 2022-05-04 | Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516998A true JP2024516998A (ja) | 2024-04-18 |
| JP2024516998A5 JP2024516998A5 (cg-RX-API-DMAC10.html) | 2025-05-14 |
Family
ID=83932546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023567923A Pending JP2024516998A (ja) | 2021-05-05 | 2022-05-04 | Shp2阻害剤とegfrチロシンキナーゼ阻害剤とを含む併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220370456A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4334317A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024516998A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022270106A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3217092A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL308225A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023012929A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022235815A1 (cg-RX-API-DMAC10.html) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019183367A1 (en) * | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| WO2020177653A1 (zh) * | 2019-03-04 | 2020-09-10 | 勤浩医药(苏州)有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| WO2015050345A1 (en) | 2013-10-01 | 2015-04-09 | Lg Electronics Inc. | Control apparatus for mobile terminal and control method thereof |
| PT3468972T (pt) | 2016-06-14 | 2020-08-21 | Novartis Ag | Compostos e composições para inibir a atividade da shp2 |
| CN110730678B (zh) * | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
| US11033547B2 (en) * | 2019-03-07 | 2021-06-15 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as SHP2 antagonists |
| EP4288057A4 (en) * | 2021-02-05 | 2025-03-12 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| WO2022235822A1 (en) * | 2021-05-05 | 2022-11-10 | Huabio International, Llc | Shp2 inhibitor monotherapy and uses thereof |
| CA3217084A1 (en) * | 2021-05-05 | 2022-11-10 | Farbod Shojaei | Combination therapies comprising shp2 inhibitors and pd-1 inhibitors |
-
2022
- 2022-05-04 MX MX2023012929A patent/MX2023012929A/es unknown
- 2022-05-04 JP JP2023567923A patent/JP2024516998A/ja active Pending
- 2022-05-04 AU AU2022270106A patent/AU2022270106A1/en active Pending
- 2022-05-04 IL IL308225A patent/IL308225A/en unknown
- 2022-05-04 WO PCT/US2022/027693 patent/WO2022235815A1/en not_active Ceased
- 2022-05-04 US US17/736,869 patent/US20220370456A1/en active Pending
- 2022-05-04 EP EP22799518.0A patent/EP4334317A4/en active Pending
- 2022-05-04 CA CA3217092A patent/CA3217092A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019183367A1 (en) * | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| WO2020177653A1 (zh) * | 2019-03-04 | 2020-09-10 | 勤浩医药(苏州)有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
Non-Patent Citations (7)
| Title |
|---|
| CANCER IMMUNOL RES, vol. 3(8), JPN6026017801, 2015, pages 936 - 945, ISSN: 0005852945 * |
| CANCER RES, vol. Vol.80,Issue21, JPN6026017797, 2020, pages 4840 - 4853, ISSN: 0005852939 * |
| CLIN CANCER RES, vol. Volume27,Issue1, JPN6026017799, January 2021 (2021-01-01), pages 342 - 354, ISSN: 0005852942 * |
| ELIFE, vol. e58204, JPN6026017809, 2020, pages 1 - 29, ISSN: 0005852940 * |
| JOURNAL OF THORACIC ONCOLOGY, vol. Volume14,Issue10,Supplement,P1.17-08, JPN6026017798, 2019, ISSN: 0005852941 * |
| JTO CLINICAL AND RESEARCH REPORTS, vol. Volume1,Issue4,100084, JPN6026017800, 2020, pages 1 - 11, ISSN: 0005852944 * |
| RESEARCH SQUARE,SHP2 INHIBITION ENHANCES THE ANTICANCER EFFECT OF OSIMERTINIB IN EGFR T790M MUTANT L, JPN6026017806, March 2021 (2021-03-01), ISSN: 0005852943 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022270106A1 (en) | 2023-12-14 |
| US20220370456A1 (en) | 2022-11-24 |
| WO2022235815A1 (en) | 2022-11-10 |
| EP4334317A4 (en) | 2025-03-05 |
| CA3217092A1 (en) | 2022-11-10 |
| MX2023012929A (es) | 2023-11-13 |
| EP4334317A1 (en) | 2024-03-13 |
| IL308225A (en) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12390469B2 (en) | SHP2 inhibitor monotherapy and uses thereof | |
| JP7075928B2 (ja) | フェニレート誘導体、調製及び医薬組成物及び使用 | |
| US20100104567A1 (en) | Pharmaceutical composition | |
| WO2006074428A2 (en) | Cxcr4 antagonists for the treatment of medical disorders | |
| EA032509B1 (ru) | Замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств | |
| JP7660801B2 (ja) | 脳透過性btk又はher2阻害剤としての化合物およびその製造方法と応用 | |
| CN112672744A (zh) | 抑制二氢乳清酸脱氢酶的方法和组合物 | |
| TWI757726B (zh) | 4(1h)-奎諾酮衍生物及其用途 | |
| CA2966452A1 (en) | Substituted bicyclic compounds as bromodomain inhibitors | |
| CN114246864B (zh) | Csf1r激酶抑制剂及其用途 | |
| US20240182429A1 (en) | Heterocyclic compound as tyk2 pseudokinase domain inhibitor, synthetic method, and use | |
| US12097203B2 (en) | Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors | |
| TW202214594A (zh) | 含硫異吲哚啉類衍生物、其製備方法及其在醫藥上的應用 | |
| JP2021514955A (ja) | プロテアソーム関連ユビキチン受容体rpn13機能を阻止する低分子およびその使用法 | |
| WO2022204721A1 (en) | Alk-5 inhibitors and uses thereof | |
| CN117677619A (zh) | 包含shp2抑制剂和pd-1抑制剂的联合疗法 | |
| CN117642398A (zh) | 包含shp2抑制剂和egfr酪氨酸激酶抑制剂的联合疗法 | |
| US20220370456A1 (en) | Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors | |
| HK40108830A (en) | Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors | |
| HK40108828A (en) | Combination therapies comprising shp2 inhibitors and pd-1 inhibitors | |
| HK40108829A (en) | Shp2 inhibitor monotherapy and uses thereof | |
| CN101137379B (zh) | 用于治疗医学病症的cxcr4拮抗剂 | |
| KR20230072446A (ko) | 암의 치료를 위한 인돌아민 2,3-디옥시게나아제 저해제와 면역체크포인트 억제제의 상승적 조합 | |
| TW202442228A (zh) | 作為tyk2抑制劑的雜環化合物及合成與應用 | |
| HK40043086A (en) | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240322 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250502 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250502 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260416 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260507 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260721 |